Example question: Bloomberg reported that supply constraints are leading to iPhone shortages. Do Trefis analysts see a meaningful impact on AAPL?
Example comment: Competition will squeeze AMZN's operating margins from 4% to 2% meaning a 10% hit to the stock according to Trefis.
Name (Required)
Email (Required, but never displayed)
* Companies:
Medtronic Logo
  • commented 4/26/14
  • tags: BSX MDT
  • Given the increasing incidence of obesity and diabetes, I think the diabetes segment is underappreciated. At the moment, they are the only ones with a pump which suspends in dangerous hypoglycemia, and it's competitors (the animus and omni pod pumps) don't come close in terms of software. Every endocrinologist I know favors Medtronic software and customer service, and seeing as how pump therapy is gaining wider acceptance in type 2 diabetic treatment (it's not just type 1 anymore), I think the diabetes segment is going to be huge in the next 3-5 years. If they successfully develop their closed loop technology algorithms, ie a true 'artificial pancreas,' it is game over for everyone else in the pump industry. [ less... ]
    Given the increasing incidence of obesity and diabetes, I think the diabetes segment is underappreciated. At the moment, they are the only ones with a pump which suspends in dangerous hypoglycemia, and it's competitors (the animus and omni pod pumps) don't come close in terms of software. Every endocrinologist I know favors Medtronic software and customer service, and seeing as how pump therapy is gaining wider acceptance in type 2 diabetic treatment (it's not just type 1 anymore), I think the diabetes segment is going to be huge in the next 3-5 years. If they successfully develop their closed loop technology algorithms, ie a true 'artificial pancreas,' it is game over for everyone else in the pump industry.
    Name (Required)
    Email (Required, but never displayed)